How to Cite
Abstract
The field of cardio-oncology has received increasing attention in recent years. This is due to the fact that the results of a large number of clinical studies on antitumor therapy, covering issues treatments side effects, including associated cardiovascular pathology, are published. Advances in treatment have led to improved survival of patients with cancer, but have also increased clinical significance of treatment side effects. Myocardium, having high metabolic activity, responds to substrate and energy imbalance under the action of increasing malignancy and toxic effects of radio- or chemotherapy. Finding of baseline risk factors, timely identification of cardiovascular diseases, ability to predict the long-term consequences of cancer treatment-associated cardiovascular side effects lead to improving of the prognosis and quality of life, avoiding of over-diagnosis cardiovascular diseases and inappropriating violation of life-saving treatment of a malignant tumor.References
Акимов А.Г, Обрезан А.Г Лечение хронической сердечной недостаточности // СПб: информМед. - 2010. - 359 с.
Бобров Л.Л., Новик А.А., Обрезан А.Г., Крысюк О.Б. Системная гемодинамика у больных лимфомами // Вестник российской Военно-медицинской Академии. - 2000. - № 1. - С. 58-63.
Косарев М.М., Обрезан А.Г., Стрельников А.А. Клинические и лабораторно-инструментальные маркеры диагностики ХСН // Журнал сердечная недостаточность. - 2010. - Т. 11 - № 3. - C. 177-184.
Шевченко Ю.Л., Бобров Л.Л., Обрезан А.Г. и др. Изменение диастолической функции левого желудочка сердца у больных с лимфогранулематозом // Клиническая медицина. - 2001. - № 6. - С. 20-24.
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines // European Heart J. - 2016. - P. 1-34.
Advani P.P., Ballman K.V., Dockter T.J. et al. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial // J. Clin Oncol. - 2016. - № 34. - P. 581-587.
Armstrong G.T., Plana J.C., Zhang N. et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging // J. Clin. Oncol. - 2012. - №30. - P. 2876-2884.
Armstrong G.T., Joshi V.M., Ness K.K. et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study // J. Am. Coll. Cardiol. - 2015. - № 65. - P. 2511-2522.
Bhave M., Akhter N., Rosen S.T. Cardiovascular toxicity of biologic agents for cancer therapy // J. Oncology (Williston Park). - 2014. - № 28. - P. 482-490.
Bowles E.J., Wellman R., Feigelson H.S. et al. Pharma-covigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study // J. Natl. Cancer Inst. - 2012. - № 104. - P. 1293-1305.
Braverman A.C., Antin J.H., Plappert M.T. et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens // J. Clin. Oncol. - 1991. - № 9. - P. 1215-1223.
Cameron D., Brown J., Dent R. et al. Adjuvant beva-cizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial // Lancet Oncol. - 2013. - № 14. - P. 933-942.
Cardinale D., Sandri M.T., Martinoni A. et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy // J. Am Coll. Cardiol. -2000. - № 36. - P. 517-522.
Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity // Prog. Cardiovasc. Dis. - 2010. - № 53. - P. 121-129.
Cardinale D., Colombo A., Lamantia G et al. Anthra-cycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy // J. Am. Coll. Cardiol. - 2010. - № 55. - P. 213-220.
Cardinale D., Colombo A., Bacchiani G. et al. Early detection of anthracycline cardiotoxicity andimprovement with heart failuretherapy // J. Circulation. - 2015. - № 131. - P. 1981-1988.
de Azambuja E., Procter M.J., van Veldhuisen D.J. et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01) // J. Clin. Oncol. - 2014. - № 32. - P.2159-2165.
Eschenhagen T, Force T., Ewer M.S. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology // Eur. J. Heart Fail. - 2011. - № 13. - P. 1-10.
Ewer M.S., Ewer S.M. Cardiotoxicity of anticancertreat-ments // Nat. Rev. Cardiol. - 2015. - № 12. - P. 620.
Felker G.M., Thompson R.E., Hare J.M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy // N. Engl. J. Med. -2000. - № 342. - P. 1077-1084.
Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 // Eur. J. Cancer. -2013. - № 49. - P. 1374-1403.
Ghatalia P., Morgan C.J., Je Y et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors // Crit. Rev. Oncol. Hematol. -2015. - № 94. - P. 228-237.
Gollerkeri A., Harrold L., Rose M. et al. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience // Int. J. Cancer. - 2001. - № 93. - P. 139-141.
Gottdiener J.S., Appelbaum F.R., Ferrans V.J. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy // Arch. Intern. Med - 1981. - Vol. 141. - P. 758-763.
Hall P.S., Harshman L.C., Srinivas S., Witteles R.M. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients // JACC Heart Fail. - 2013. - № 1. - P. 72-78.
Herrmann J., Lerman A., Sandhu N.P. et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology // Mayo Clin. Proc. - 2014. - № 89. - P. 1287-1306.
Ky B., Carver J.R. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy // Heart Fail Clin. - 2011. - № 7. - P. 323-331.
Limat S., Daguindau E., Cahn J.Y. et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma // J. Clin. Pharm Ther. - 2014. - Vol. 39. - № 168. - P. 174.
Moja L., Tagliabue L., Balduzzi S. et al. Trastuzumab containing regimens for early breast cancer // Cochrane Database Syst Rev. - 2012. - №4 - CD006243.
Oeffinger K.C., Mertens A.C., Sklar C.A. et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer // N Engl J Med -2006. - №355 - Pp.1572-1582.
Russell S.D., Lyon A., Lenihan D.J. et al. Serial echocar-diographic assessment of patients with relapsed multiple myeloma receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 Endeavor Trial (NCT01568866).// Blood. -2015. - №126. - abstract 4250.
Sawaya H., Sebag I.A., Plana J.C. et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthra-cyclines, taxanes, and trastuzumab.// Circ Cardiovasc Imaging. - 2012. - № 5. - P. 596-603.
Sawyer D.B., Peng X., Chen B. et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? // Prog. Cardiovasc. Dis. - 2010. -№ 53. - P. 105-113.
Shah M.A. Update on metastatic gastric and esophageal cancers // J. Clin. Oncol. - 2015. - № 33. - P. 1760-1769.
Shelburne N., Adhikari B., Brell J. et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities // J. Natl. Cancer Inst. -2014. - № 106.
Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics, 2012 // CA Cancer J. Clin. -2012. - № 62. - P. 220-241.
Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management // Eur. Heart J. - 2013 - № 34. - P. 1102-1111.
Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials // J. Cancer. - 2003. - № 97. - P. 2869-2879.
Thavendiranathan P., Poulin F, Lim K.D. et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review // J. Am Coll. Cardiol. - 2014. - № 63. - P. 2751-2768.
Valent P., Hadzijusufovic E., Schernthaner G.H. et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors // J. Blood. - 2015. - № 125. - P. 901-906.
Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities // J. Am Coll. Cardiol. - 2014. - № 64. - P. 938-945.
Voigt J.U., Pedrizzetti G., Lysyansky P. et al. Definitions for a common standard for 2d speckle tracking echocardiography: consensus document of the EACVI/AsE/ Industry Task Force to standardize deformation imaging // Eur. Heart J. Cardiovasc. Imaging. - 2015. - № 16. - P. 1-11.
Von Hoff D.D., Layard M.W., Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure // Ann Intern. Med. - 1979. - № 91. - P 710-717.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019